News
Background In the Phase 3 MycarinG (NCT03971422) study, one cycle (six once-weekly subcutaneous infusions) of rozanolixizumab 7mg/kg or 10mg/kg significantly improved myasthenia gravis (MG)-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback